With 0.79 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.21 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $403.88 whereas the lowest price it dropped to was $393.0. The 52-week range on VRTX shows that it touched its highest point at $448.40 and its lowest point at $316.43 during that stretch. It currently has a 1-year price target of $464.29. Beta for the stock currently stands at 0.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VRTX was up-trending over the past week, with a rise of 1.07%, but this was down by -4.96% over a month. Three-month performance dropped to -7.50% while six-month performance rose 7.67%. The stock gained 19.81% in the past year, while it has lost -2.26% so far this year. A look at the trailing 12-month EPS for VRTX yields 13.89 with Next year EPS estimates of 18.17. For the next quarter, that number is 4.08. This implies an EPS growth rate of 8.56% for this year and 9.90% for next year. EPS is expected to grow by 12.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 11.42%.
Float and Shares Shorts:
At present, 257.70 million VRTX shares are outstanding with a float of 257.54 million shares on hand for trading. On 2024-04-15, short shares totaled 4.03 million, which was 155.99999999999997 higher than short shares on 1710460800. In addition to Dr. Jeffrey Marc Leiden M.D., Ph.D. as the firm’s Executive Chairman, Dr. Reshma Kewalramani FASN, M.D. serves as its CEO, President & Director.
Institutional Ownership:
Through their ownership of 0.97310996 of VRTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, VRTX reported revenue of $2517700000.0 and operating income of $956000000.0. The EBITDA in the recently reported quarter was $1184700000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VRTX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
